Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT ID: NCT00233454

Last Updated: 2018-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31
• Study Completion Date: 2011-04-16

Brief Summary

The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)

Detailed Description

This study assesses the activity and safety profile of twice-daily oral doses of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without associated clonal hematological non-mast cell lineage disease (AHNMD).

Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL) are characterized by excessive bone marrow production of mast cells which can can infiltrate tissues and release harmful substances, resulting in organ damage. These diseases have very limited treatment options and poor prognosis. Existing treatments for in advanced mast cell disease, eg, interferon-alpha; corticosteroids; and/or cladribine, exhibit low response rates that are usually partial in nature.

Conditions

Systemic Mastocytosis, Aggressive (ASM); Leukemia, Mast Cell; Hematological Non-mast Cell Lineage Disease (AHNMD)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Midostaurin

100 mg midostaurin twice daily as oral capsules

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR

Interventions

Midostaurin

Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR

Intervention Type: DRUG

Other Intervention Names

PKC412; CGP41251; CGP41231

Eligibility Criteria

Inclusion Criteria

• At least 18 years of age.
• Karnofsky performance status (KPS) of > 30% (equivalent to ECOG 0 to 3)
• Mast cell disease, histologically confirmed and documented to be

• Aggressive systemic mastocytosis (ASM) OR
• Mast cell leukemia (MCL) meeting the following criteria

• Meets criteria for systemic mastocytosis
• Biopsy indicates diffuse infiltration by atypical, immature mast cells
• Bone marrow aspirate smears show at least 20% mast cells
• Confirmed availability of tissue sample within 6 months prior to entry into study, for evaluation of KIT mutation status of the tumor cells. Subjects who have systemic mastocytosis PLUS eosinophilia AND known positivity for FIP1L1-PDGFR-alpha fusion are eligible only if they have demonstrated relapse or disease progression on prior imatinib therapy
• Blood levels of liver enzymes within normal limits (EXCEPTION: If the sole cause of elevated blood levels of liver enzymes is ASM/MCL, then AST and ALT ≤ 4X upper limit of normal (ULN), and/or bilirubin ≤ 4X ULN)
• Serum creatinine < 2.0 mg/dL
• If ANC < 1500/mm3; Hb < 10 g/dL; platelets < 75,000/mm3; AND/OR other blood values are > grade 2, then the relationship of these cytopenia(s) should be established as related to ASM or MCL on the basis of presence of mast cell infiltrate in the screening bone marrow exam and/or the presence of disease-related hypersplenism
• Prior use of glucocorticoids must be tapered off within 14 days of Day 1 of midostaurin treatment (EXCEPTION: If in the opinion of the investigator, the subject can be tapered off glucocorticoids, then dosage should be tapered to the minimal dose possible before first treatment with midostaurin)
• Negative serum pregnancy test for women of childbearing potential within 48 hours prior to administration of study drug
• Written informed consent.
• Anyone of reproductive potential must agree to use barrier contraceptives for the duration of the study
• Women of childbearing potential must have a negative serum pregnancy test 48 hours prior to administration of study drug, and must agree to:

• Use barrier contraception for the duration of the study
• Use barrier contraception for 3 months post-study
• Not breast-feed

Exclusion Criteria

• Active pulmonary disease based on physical assessment or lateral chest X-ray, considered by the investigator to be unrelated to mastocytosis
• Any pulmonary infiltrate or abnormality on the baseline chest X-ray known to be new in the previous 4 weeks (EXCEPTION: pleural effusion related to systemic mastocytosis, eg, secondary to ascites, AND not causing symptomatic respiratory complaints, may be eligible)
• Cardiovascular disease, including congestive heart failure
• Myocardial infarction within 6 months
• Poorly-controlled hypertension with any Grade 3/4 cardiac problems (per New York Heart Association Criteria)
• Uncontrolled diabetes
• Chronic renal disease
• Active uncontrolled infection
• Known malignant disease involving the central nervous system (CNS)
• Known confirmed diagnosis of HIV infection or active viral hepatitis.
• Any other known disease, or concurrent severe and/or uncontrolled medical condition which could compromise participation in the study, including but not limited to:
• Received any investigational agent, chemotherapy, or 2-chlorodeoxyadenosine (2-CdA) within 30 days prior to Day 1 of PKC412 treatment.
• Received interferon-alpha within 30 days prior to Day 1 of midostaurin treatment.
• Received hematopoietic growth factor support within 14 days of Day 1 of midostaurin treatment.
• Any surgical procedure, excluding central venous catheter placement or other minor procedures (eg, skin biopsy) within 14 days of Day 1 of midostaurin treatment
• Pregnant or breast-feeding
• Unwilling or unable to comply with the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Jason Robert Gotlib

OTHER

Sponsor Role: lead

Responsible Party

Jason Robert Gotlib

Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jason Robert Gotlib

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Stanford University School of Medicine

Stanford, California, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Washington University-St. Louis

St Louis, Missouri, United States

Countries

United States

References

Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20;24(24):3904-11. doi: 10.1200/JCO.2006.06.9500.

Reference Type: BACKGROUND

PMID: 16921041 (View on PubMed)

Gotlib JR, George TI, Linder A, et al. "Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results." Blood. 16 November 2006;108(11)16:abs3609

Reference Type: RESULT

Gotlib JR, George TI, Corless C, et al. "The KIT Tyrosine Kinase Inhibitor Midostaurin (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis(ASM): Interim Results of a Phase 2 Trial." Blood. 16 November 2007;110(11):abs 3536

Reference Type: RESULT

Gotlib JR, DeAngelo DJ, George TI, et al. "KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial." Blood. 19 November 2010;116(21):abs316

Reference Type: RESULT

Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.

Reference Type: RESULT

PMID: 27355533 (View on PubMed)

DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, Westervelt P, Merker JD, Berube C, Coutre S, Liedtke M, Medeiros B, Sternberg D, Dutreix C, Ruffie PA, Corless C, Graubert TJ, Gotlib J. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018 Feb;32(2):470-478. doi: 10.1038/leu.2017.234. Epub 2017 Jul 24.

Reference Type: RESULT

PMID: 28744009 (View on PubMed)

Other Identifiers

95242

Identifier Type: OTHER

Identifier Source: secondary_id

HEMMPD0003

Identifier Type: OTHER

Identifier Source: secondary_id

CPKC412D2201

Identifier Type: OTHER

Identifier Source: secondary_id

2213

Identifier Type: OTHER

Identifier Source: secondary_id

IRB-13704

Identifier Type: -

Identifier Source: org_study_id